Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes - the Role of Glucose Homeostasis on Uptake of Beta-cell Tracer Exendin-4

Registration

Registration

NCT04733508

Acronym

GLP1R-T2D

Study type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Status

UNKNOWN

Enrollment

28

Start

2019-11-01

Primary completion

2022-06-01

Lead sponsor

Radboud University Medical Center

Conditions

Diabetes Mellitus; Diabetes Mellitus, Type 2

Interventions

DRUG:111In-DTPA-exendin-4; DRUG:IRDye800CW-exendin-4

Results posted

FALSE

Individual participant data sharing

UNDECIDED

Registered primary outcomes

• Pancreatic exendin uptake 111In-DTPA exendin-4 [111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using ex vivo SPECTof the resected tissue one day after surgery]
• Pancreatic exendin uptake 111In-DTPA exendin-4 [111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined with tissue autoradiography immediately after resection]
• Beta cell function [The glucose tolerance test will be performed within a week before planned surgery]
• Blood glucose levels [Blood glucose levels will be continuously monitored a week prior to surgery]
• HbA1C levels [HbA1C levels will be determined within a week before planned surgery]
• Pancreatic exendin uptake IRDye800CW-exendin-4 [IRDye800CW-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using microscopy in the excised tissue]
• Gene expression [Gene expression will be determined in the excised pancreatic tissue immediately after resection]